Best Ipamorelin Providers in 2026 — Ranked & Reviewed

Ipamorelin is a selective ghrelin-receptor agonist that stimulates growth-hormone release without significantly elevating cortisol, prolactin, or ACTH — the selectivity that set it apart from earlier GH-releasing peptides such as GHRP-2. It is prescription-only in the US and, like its common stack partner CJC-1295, currently sits in regulatory limbo. See below for the current status.

New to Ipamorelin? Read our full Ipamorelin guide — evidence, dosing, safety and side effects.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

Why there’s no ranking here yet

Ipamorelin's nomination for the FDA's Section 503A Bulk Drug Substances List was withdrawn, and it is not on that list today — so no 503A compounding pharmacy has a current lawful basis to sell it, regardless of what any individual provider's page claims. It was not part of the FDA advisory committee's July 2026 positive recommendation (unlike BPC-157, TB-500, and MOTS-c), so we don't have a clear approval timeline to point to. We'll rank providers here the moment we can confirm one is legally compliant.

We’d rather show nothing than list a provider who can’t legally sell this yet. We’re tracking the FDA’s decision and will rank compliant providers here the moment one exists.

How we rank & what counts as “legit”

Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.

Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].

Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Frequently Asked Questions

Each provider is evaluated across six weighted dimensions: Value (25%), Effectiveness (25%), User Experience (15%), Trust & Safety (15%), Accessibility (10%), and Support (10%). We research publicly available information, user reviews, clinical evidence, and pricing data, then compute a weighted overall score out of 10.
Each provider's score is computed independently using the six-dimension methodology, and a commercial relationship never changes a provider's underlying score — you can see every provider's full score on its card. Some providers have affiliate agreements with us, meaning we earn a commission if you click through and make a purchase. On our highest-commercial-intent lists — including the semaglutide, tirzepatide, compounded and cheapest molecule lists, the weight-loss injection and shot lists, and the fitness-app list — we feature affiliate partners in the top positions; on every other list the order follows the score (or, for the cheapest lists, the lowest price) directly. This placement is disclosed here and on our methodology and affiliate-disclosure pages.
Sources & methodology — as of September 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings